

In the format provided by the authors and unedited.

A catalog of genetic loci associated with kidney function from analyses of a million individuals

Matthias Wuttke^{1,2,267}, Yong Li^{1,267}, Man Li^{3,267}, Karsten B. Sieber^{4,267}, Mary F. Feitosa^{5,267}, Mathias Gorski^{6,7,267}, Adrienne Tin^{8,9}, Lihua Wang⁵, Audrey Y. Chu¹⁰, Anselm Hoppmann¹, Holger Kirsten^{11,12}, Ayush Giri^{13,14}, Jin-Fang Chai¹⁵, Gardar Sveinbjornsson¹⁶, Bamidele O. Tayo¹⁷, Teresa Nutile¹⁸, Christian Fuchsberger¹⁹, Jonathan Marten²⁰, Massimiliano Cocca²¹, Sahar Ghasemi^{22,23}, Yizhe Xu³, Katrin Horn^{11,12}, Damia Noce¹⁹, Peter J. van der Most²⁴, Sanaz Sedaghat²⁵, Zhi Yu^{8,26}, Masato Akiyama^{27,28}, Saima Afaq^{29,30}, Tarunveer S. Ahluwalia³¹, Peter Almgren³², Najaf Amin²⁵, Johan Ärnlöv^{33,34}, Stephan J. L. Bakker³⁵, Nisha Bansal^{36,37}, Daniela Baptista³⁸, Sven Bergmann^{39,40,41}, Mary L. Biggs^{42,43}, Ginevra Biino⁴⁴, Michael Boehnke⁴⁵, Eric Boerwinkle⁴⁶, Mathilde Boissel⁴⁷, Erwin P. Bottinger^{48,49}, Thibaud S. Boutin²⁰, Hermann Brenner^{50,51}, Marco Brumat⁵², Ralph Burkhardt^{12,53,54}, Adam S. Butterworth^{55,56}, Eric Campana⁵², Archie Campbell⁵⁷, Harry Campbell⁵⁸, Mickaël Canouil⁴⁷, Robert J. Carroll⁵⁹, Eulalia Catamo²¹, John C. Chambers^{29,60,61,62,63}, Miao-Ling Chee⁶⁴, Miao-Li Chee⁶⁴, Xu Chen⁶⁵, Ching-Yu Cheng^{64,66,67}, Yurong Cheng¹, Kaare Christensen⁶⁸, Renata Cifkova^{69,70}, Marina Ciullo^{18,71}, Maria Pina Concas²¹, James P. Cook⁷², Josef Coresh⁸, Tanguy Corre^{39,40,73}, Cinzia Felicita Sala⁷⁴, Daniele Cusi^{75,76}, John Danesh⁷⁷, E. Warwick Daw⁵, Martin H. de Borst³⁵, Alessandro De Grandi¹⁹, Renée de Mutsert⁷⁸, Aiko P. J. de Vries⁷⁹, Frauke Degenhardt⁸⁰, Graciela Delgado⁸¹, Ayse Demirkan²⁵, Emanuele Di Angelantonio^{82,83}, Katalin Dittrich^{84,85}, Jasmin Divers⁸⁶, Rajkumar Dorajoo⁸⁷, Kai-Uwe Eckardt^{88,89}, Georg Ehret³⁸, Paul Elliott^{90,91,92,93}, Karlhans Endlich^{23,94}, Michele K. Evans⁹⁵, Janine F. Felix^{25,96,97}, Valencia Hui Xian Foo⁶⁴, Oscar H. Franco^{25,98}, Andre Franke⁸⁰, Barry I. Freedman⁹⁹, Sandra Freitag-Wolf¹⁰⁰, Yechiel Friedlander¹⁰¹, Philippe Froguel^{47,102}, Ron T. Gansevoort³⁵, He Gao⁹⁰, Paolo Gasparini^{21,52}, J. Michael Gaziano¹⁰³, Vilmantas Giedraitis¹⁰⁴, Christian Gieger^{105,106,107}, Giorgia Grotto^{21,52}, Franco Giulianini¹⁰⁸, Martin Gögele¹⁹, Scott D. Gordon¹⁰⁹, Daniel F. Gudbjartsson¹⁶, Vilmundur Gudnason^{110,111}, Toomas Haller¹¹², Pavel Hamet^{113,114}, Tamara B. Harris¹¹⁵, Catharina A. Hartman¹¹⁶, Caroline Hayward²⁰, Jacklyn N. Hellwege^{117,118,119}, Chew-Kiat Heng^{120,121}, Andrew A. Hicks¹⁹, Edith Hofer^{122,123}, Wei Huang^{124,125}, Nina Hutri-Kähönen^{126,127}, Shih-Jen Hwang^{128,129}, M. Arfan Ikram²⁵, Olafur S. Indridason¹³⁰, Erik Ingelsson^{131,132,133,134}, Marcus Ising¹³⁵, Vincent W. V. Jaddoe^{25,96,97}, Johanna Jakobsdottir¹³⁶, Jost B. Jonas^{137,138}, Peter K. Joshi⁵⁸, Navya Shilpa Josyula¹³⁹, Bettina Jung⁶, Mika Kähönen^{140,141}, Yoichiro Kamatani^{27,142}, Candace M. Kammerer¹⁴³, Masahiro Kanai^{27,144}, Mika Kastarinen¹⁴⁵, Shona M. Kerr²⁰, Chiea-Chuen Khor^{64,87}, Wieland Kiess^{12,84,85}, Marcus E. Kleber⁸¹, Wolfgang Koenig^{146,147,148}, Jaspal S. Kooner^{61,62,63,149}, Antje Körner^{12,84,85}, Peter Kovacs¹⁵⁰, Aldi T. Kraja⁵, Alena Krajcoviechova^{69,70}, Holly Kramer^{17,151}, Bernhard K. Krämer⁸¹, Florian Kronenberg¹⁵², Michiaki Kubo¹⁵³, Brigitte Kühnel¹⁰⁵, Mikko Kuokkanen^{154,155}, Johanna Kuusisto^{145,156}, Martina La Bianca²¹, Markku Laakso^{145,156}, Leslie A. Lange¹⁵⁷, Carl D. Langefeld⁸⁶, Jeannette Jen-Mai Lee¹⁵, Benjamin Lehne²⁹,

Terho Lehtimäki^{158,159}, Wolfgang Lieb¹⁶⁰, Lifelines Cohort Study¹⁶¹, Su-Chi Lim^{15,162}, Lars Lind¹⁶³, Cecilia M. Lindgren^{164,165}, Jun Liu²⁵, Jianjun Liu^{87,166}, Markus Loeffler^{11,12}, Ruth J. F. Loos^{48,167}, Susanne Lucae¹³⁵, Mary Ann Lukas¹⁶⁸, Leo-Pekka Lyytikäinen^{158,159}, Reedik Mägi¹¹², Patrik K. E. Magnusson⁶⁵, Anubha Mahajan^{169,170}, Nicholas G. Martin¹⁰⁹, Jade Martins¹⁷¹, Winfried März^{172,173,174}, Deborah Mascalconi¹⁹, Koichi Matsuda¹⁷⁵, Christa Meisinger^{176,177}, Thomas Meitinger^{147,178,179}, Olle Melander¹⁸⁰, Andres Metspalu¹¹², Evgenia K. Mikaelsdottir¹⁶, Yuri Milaneschi¹⁸¹, Kozeta Miliku^{25,96,97}, Pashupati P. Mishra^{158,159}, V. A. Million Veteran Program¹⁶¹, Karen L. Mohlke¹⁸², Nina Mononen^{158,159}, Grant W. Montgomery¹⁸³, Dennis O. Mook-Kanamori^{78,184}, Josyf C. Mychaleckyj¹⁸⁵, Girish N. Nadkarni^{48,186}, Mike A. Nalls^{187,188}, Matthias Nauck^{23,189}, Kjell Nikus^{190,191}, Boting Ning¹⁹², Ilja M. Nolte²⁴, Raymond Noordam¹⁹³, Jeffrey O'Connell¹⁹⁴, Michelle L. O'Donoghue^{195,196}, Isleifur Olafsson¹⁹⁷, Albertine J. Oldehinkel¹¹⁶, Marju Orho-Melander³², Willem H. Ouwehand⁷⁷, Sandosh Padmanabhan¹⁹⁸, Nicholette D. Palmer¹⁹⁹, Runolfur Palsson^{111,130}, Brenda W. J. H. Penninx¹⁸¹, Thomas Perls²⁰⁰, Markus Perola²⁰¹, Mario Pirastu²⁰², Nicola Pirastu⁵⁸, Giorgio Pistis²⁰³, Anna I. Podgornaia¹⁰, Ozren Polasek^{204,205}, Belen Ponte²⁰⁶, David J. Porteous^{57,207}, Tanja Poulain¹², Peter P. Pramstaller¹⁹, Michael H. Preuss⁴⁸, Bram P. Prins⁵⁵, Michael A. Province⁵, Ton J. Rabelink^{79,208}, Laura M. Raffield¹⁸², Olli T. Raitakari^{209,210}, Dermot F. Reilly¹⁰, Rainer Rettig²¹¹, Myriam Rheinberger⁶, Kenneth M. Rice⁴³, Paul M. Ridker^{108,212}, Fernando Rivadeneira^{25,213}, Federica Rizzi^{214,215}, David J. Roberts²¹⁶, Antonietta Robino²¹, Peter Rossing³¹, Igor Rudan⁵⁸, Rico Rueedi^{39,40}, Daniela Ruggiero^{18,71}, Kathleen A. Ryan²¹⁷, Yasaman Saba²¹⁸, Charumathi Sabanayagam⁶⁴, Veikko Salomaa²⁰¹, Erika Salvi^{214,219}, Kai-Uwe Saum⁵⁰, Helena Schmidt²²⁰, Reinhold Schmidt¹²², Ben Schöttker^{50,51}, Christina-Alexandra Schulz³², Nicole Schupf^{221,222,223}, Christian M. Shaffer⁵⁹, Yuan Shi⁶⁴, Albert V. Smith¹¹¹, Blair H. Smith²²⁴, Nicole Soranzo²²⁵, Cassandra N. Spracklen¹⁸², Konstantin Strauch^{226,227}, Heather M. Stringham⁴⁵, Michael Stumvoll²²⁸, Per O. Svensson^{229,230}, Silke Szymczak¹⁰⁰, E-Shyong Tai^{15,166,231}, Salman M. Tajuddin⁹⁵, Nicholas Y. Q. Tan⁶⁴, Kent D. Taylor²³², Andrej Teren^{12,233}, Yih-Chung Tham⁶⁴, Joachim Thiery^{12,53}, Chris H. L. Thio²⁴, Hauke Thomsen²³⁴, Gudmar Thorleifsson¹⁶, Daniela Toniolo⁷⁴, Anke Tönjes²²⁸, Johanne Tremblay^{113,235}, Ioanna Tzoulaki^{90,236}, André G. Uitterlinden²¹³, Simona Vaccargiu²⁰², Rob M. van Dam^{15,166}, Pim van der Harst^{237,238,239}, Cornelia M. van Duijn²⁵, Digna R. Velez Edward^{119,240}, Niek Verweij²³⁷, Suzanne Vogelesang^{25,96,97}, Uwe Völker^{23,241}, Peter Vollenweider²⁴², Gerard Waeber²⁴², Melanie Waldenberger^{105,106,147}, Lars Wallentin^{243,244}, Ya Xing Wang¹³⁸, Chaolong Wang^{87,245}, Dawn M. Waterworth⁴, Wen Bin Wei²⁴⁶, Harvey White²⁴⁷, John B. Whitfield¹⁰⁹, Sarah H. Wild²⁴⁸, James F. Wilson^{20,58}, Mary K. Wojczynski⁵, Charlene Wong⁶⁷, Tien-Yin Wong^{64,67}, Liang Xu¹³⁸, Qiong Yang¹⁹², Masayuki Yasuda^{64,249}, Laura M. Yerges-Armstrong⁴, Weihua Zhang^{61,90}, Alan B. Zonderman⁹⁵, Jerome I. Rotter^{232,250,251}, Murielle Bochud⁷³, Bruce M. Psaty^{252,253}, Veronique Vitart²⁰, James G. Wilson²⁵⁴, Abbas Dehghan^{29,90}, Afshin Parsa^{255,256}, Daniel I. Chasman^{108,212}, Kevin Ho^{257,258}, Andrew P. Morris^{72,169}, Olivier Devuyst²⁵⁹, Shreeram Akilesh^{37,260}, Sarah A. Pendergrass²⁶¹, Xueling Sim¹⁵, Carsten A. Böger^{6,262}, Yukinori Okada^{263,264}, Todd L. Edwards^{119,265}, Harold Snieder²⁴, Kari Stefansson¹⁶, Adriana M. Hung^{119,266}, Iris M. Heid^{7,268}, Markus Scholz^{11,12,268}, Alexander Teumer^{22,23,268}, Anna Köttgen^{1,8,268*} and Cristian Pattaro^{19,268*}

¹Institute of Genetic Epidemiology, Department of Biometry, Epidemiology and Medical Bioinformatics, Faculty of Medicine and Medical Center–University of Freiburg, Freiburg, Germany. ²Renal Division, Department of Medicine IV, Faculty of Medicine and Medical Center–University of Freiburg, Freiburg, Germany. ³Division of Nephrology and Hypertension, Department of Medicine, University of Utah, Salt Lake City, USA. ⁴Target Sciences–Genetics, GlaxoSmithKline, Collegeville, PA, USA. ⁵Division of Statistical Genomics, Department of Genetics, Washington University School of Medicine, St. Louis, MO, USA. ⁶Department of Nephrology, University Hospital Regensburg, Regensburg, Germany. ⁷Department of Genetic Epidemiology, University of Regensburg, Regensburg, Germany. ⁸Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. ⁹Welch Center for Prevention, Epidemiology and Clinical Research, Baltimore, MD, USA. ¹⁰Genetics, Merck & Co., Inc, Kenilworth, NJ, USA. ¹¹Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany. ¹²LIFE Research Center for Civilization Diseases, University of Leipzig, Leipzig, Germany. ¹³Division of Quantitative Sciences, Department of Obstetrics & Gynecology, Vanderbilt Genetics Institute, Vanderbilt Epidemiology Center, Institute for Medicine and Public Health, Vanderbilt University Medical Center, Nashville, TN, USA. ¹⁴Biomedical Laboratory Research and Development, Tennessee Valley Healthcare System (626)/Vanderbilt University, Nashville, TN, USA. ¹⁵Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore, Singapore. ¹⁶deCODE Genetics/Amgen, Inc., Reykjavik, Iceland. ¹⁷Department of Public Health Sciences, Loyola University Chicago, Maywood, IL, USA. ¹⁸Institute of Genetics and Biophysics ‘Adriano Buzzati-Traverso’–CNR, Naples, Italy. ¹⁹Eurac Research, Institute for Biomedicine (affiliated with the University of Lübeck), Bolzano, Italy. ²⁰Medical Research Council Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK. ²¹Institute for Maternal and Child Health, IRCCS ‘Burlo Garofolo’, Trieste, Italy. ²²Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany. ²³DZHK (German Center for Cardiovascular Research), partner site Greifswald, Greifswald, Germany. ²⁴Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. ²⁵Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands. ²⁶Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. ²⁷Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences (IMS), Yokohama, Japan. ²⁸Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. ²⁹Department of Epidemiology and Biostatistics, Faculty of Medicine, School of Public Health, Imperial College London, London, UK. ³⁰Institute of Public Health & Social Sciences, Khyber Medical University, Peshawar, Pakistan. ³¹Steno Diabetes Center Copenhagen, Gentofte, Denmark. ³²Diabetes and Cardiovascular Disease–Genetic Epidemiology, Department of Clinical Sciences in Malmö, Lund University, Malmö, Sweden. ³³Division of Family Medicine and Primary Care, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden. ³⁴School of Health and Social Studies, Dalarna University, Stockholm, Sweden. ³⁵Division of Nephrology, Department of Internal Medicine, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. ³⁶Division of Nephrology, University of Washington, Seattle, WA, USA. ³⁷Kidney Research Institute, University of Washington, Seattle, WA, USA. ³⁸Cardiology, Geneva University Hospitals, Geneva, Switzerland. ³⁹Department of Computational Biology, University of Lausanne, Lausanne, Switzerland. ⁴⁰Swiss Institute of Bioinformatics, Lausanne, Switzerland. ⁴¹Department of Integrative Biomedical Sciences, University of Cape Town, Cape Town, South Africa. ⁴²Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, USA. ⁴³Department of Biostatistics, University of Washington, Seattle, WA, USA. ⁴⁴Institute of Molecular Genetics, National Research Council of Italy, Pavia, Italy. ⁴⁵Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, MI, USA. ⁴⁶Human Genetics Center, University of Texas Health Science Center, Houston, TX, USA. ⁴⁷CNRS UMR 8199, European Genomic Institute for Diabetes (EGID), Institut Pasteur de Lille, University of Lille, Lille, France. ⁴⁸Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ⁴⁹Digital Health Center, Hasso Plattner Institute and University of Potsdam, Potsdam, Germany. ⁵⁰Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany. ⁵¹Network Aging Research, University of Heidelberg, Heidelberg, Germany. ⁵²Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy. ⁵³Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University of Leipzig, Leipzig, Germany. ⁵⁴Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Regensburg, Germany. ⁵⁵MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. ⁵⁶National Institute for Health Research Blood and Transplant Research Unit in Donor Health and Genomics, University of Cambridge, Cambridge, UK. ⁵⁷Center for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK. ⁵⁸Center for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK. ⁵⁹Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA. ⁶⁰Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore. ⁶¹Department of Cardiology, Ealing Hospital, Middlesex, UK. ⁶²Imperial College Healthcare NHS Trust, Imperial College London, London, UK. ⁶³MRC–PHE Center for Environment and Health, School of Public Health, Imperial College London, London, UK. ⁶⁴Singapore Eye Research Institute, Singapore National Eye Center, Singapore, Singapore. ⁶⁵Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. ⁶⁶Ophthalmology and Visual Sciences Academic Clinical Program (Eye ACP), Duke–NUS Medical School, Singapore, Singapore. ⁶⁷Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore and National University Health System, Singapore, Singapore. ⁶⁸Unit of Epidemiology, Biostatistics and Biodemography, Department of Public Health, Southern Denmark University, Odense, Denmark. ⁶⁹Center for Cardiovascular Prevention, Charles University in Prague, First Faculty of Medicine and Thomayer Hospital, Prague, Czech Republic. ⁷⁰Department of Medicine II, Charles University in Prague, First Faculty of Medicine, Prague, Czech Republic. ⁷¹IRCCS Neurome, Pozzilli, Italy. ⁷²Department of Biostatistics, University of Liverpool, Liverpool, UK. ⁷³Institute of Social and Preventive Medicine, Lausanne University Hospital, Lausanne, Switzerland. ⁷⁴San Raffaele Research Institute, Milan, Italy. ⁷⁵Institute of Biomedical Technologies, National Research Council of Italy, Milan, Italy. ⁷⁶Bio4Dreams–Business Nursery for Life Sciences, Milan, Italy. ⁷⁷Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge, UK. ⁷⁸Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands. ⁷⁹Section of Nephrology, Department of Internal Medicine, Leiden University Medical Center, Leiden, the Netherlands. ⁸⁰Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany. ⁸¹Department of Medicine (Nephrology, Hypertensiology, Rheumatology, Endocrinology, Diabetology), Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. ⁸²Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. ⁸³NHS Blood and Transplant, Cambridge, UK. ⁸⁴Department of Women and Child Health, Hospital for Children and Adolescents, University of Leipzig, Leipzig, Germany. ⁸⁵Center for Pediatric Research, University of Leipzig, Leipzig, Germany. ⁸⁶Public Health Sciences–Biostatistics, Wake Forest School of Medicine, Winston-Salem, NC, USA. ⁸⁷Genome Institute of Singapore, Agency for Science Technology and Research, Singapore, Singapore. ⁸⁸Intensive Care Medicine, Charité, Berlin, Germany. ⁸⁹Department of Nephrology and Hypertension, Friedrich Alexander University Erlangen–Nürnberg (FAU), Erlangen, Germany. ⁹⁰Department of Epidemiology and Biostatistics, MRC–PHE Center for Environment and Health, School of Public Health, Imperial College London, London, UK. ⁹¹Imperial College NIHR Biomedical Research Center, Imperial College London, London, UK. ⁹²Dementia Research Institute, Imperial College London, London, UK. ⁹³Health Data Research UK–London, London, UK. ⁹⁴Department of Anatomy and Cell Biology, University Medicine Greifswald, Greifswald, Germany. ⁹⁵Laboratory of Epidemiology and Population Sciences, National Institute on Aging, Intramural Research Program, US National Institutes of Health, Baltimore, MD, USA. ⁹⁶Generation R Study Group, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands. ⁹⁷Department of Pediatrics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. ⁹⁸Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland. ⁹⁹Section on Nephrology, Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA. ¹⁰⁰Institute of Medical Informatics and Statistics, Kiel University, University Hospital Schleswig–Holstein, Kiel, Germany. ¹⁰¹School of

Public Health and Community Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. ¹⁰²Department of Genomics of Common Disease, Imperial College London, London, UK. ¹⁰³Massachusetts Veterans Epidemiology Research and Information Center, VA Cooperative Studies Program, VA Boston Healthcare System, Boston, MA, USA. ¹⁰⁴Molecular Geriatrics, Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden. ¹⁰⁵Research Unit of Molecular Epidemiology, Helmholtz Zentrum München—German Research Center for Environmental Health, Neuherberg, Germany. ¹⁰⁶Institute of Epidemiology, Helmholtz Zentrum München—German Research Center for Environmental Health, Neuherberg, Germany. ¹⁰⁷German Center for Diabetes Research (DZD), Neuherberg, Germany. ¹⁰⁸Division of Preventive Medicine, Brigham and Women's Hospital, Boston, MA, USA. ¹⁰⁹QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia. ¹¹⁰Icelandic Heart Association, Kopavogur, Iceland. ¹¹¹Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland. ¹¹²Estonian Genome Center, Institute of Genomics, University of Tartu, Tartu, Estonia. ¹¹³Montreal University Hospital Research Center, CHUM, Montreal, Quebec, Canada. ¹¹⁴Medpharmgene, Montreal, Quebec, Canada. ¹¹⁵Laboratory of Epidemiology and Population Sciences, National Institute on Aging, Intramural Research Program, US National Institutes of Health, Bethesda, MD, USA. ¹¹⁶Interdisciplinary Center of Psychopathology and Emotion Regulation (ICPE), University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. ¹¹⁷Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, USA. ¹¹⁸Division of Epidemiology, Department of Medicine, Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, USA. ¹¹⁹Department of Veteran's Affairs, Tennessee Valley Healthcare System (626)/Vanderbilt University, Nashville, TN, USA. ¹²⁰Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. ¹²¹Khoo Teck Puat—National University Children's Medical Institute, National University Health System, Singapore, Singapore. ¹²²Clinical Division of Neurogeriatrics, Department of Neurology, Medical University of Graz, Graz, Austria. ¹²³Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria. ¹²⁴Department of Genetics, Shanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center, Shanghai, China. ¹²⁵Shanghai Industrial Technology Institute, Shanghai, China. ¹²⁶Department of Pediatrics, Tampere University Hospital, Tampere, Finland. ¹²⁷Department of Pediatrics, Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland. ¹²⁸NHLBI's Framingham Heart Study, Framingham, MA, USA. ¹²⁹The Center for Population Studies, NHLBI, Framingham, MA, USA. ¹³⁰Division of Nephrology, Internal Medicine Services, Landspítali—The National University Hospital of Iceland, Reykjavik, Iceland. ¹³¹Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA. ¹³²Stanford Cardiovascular Institute, Stanford University, Stanford, CA, USA. ¹³³Molecular Epidemiology and Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Uppsala, Sweden. ¹³⁴Stanford Diabetes Research Center, Stanford University, Stanford, CA, USA. ¹³⁵Max Planck Institute of Psychiatry, Munich, Germany. ¹³⁶The Center of Public Health Sciences, University of Iceland, Reykjavik, Iceland. ¹³⁷Department of Ophthalmology, Medical Faculty Mannheim, University Heidelberg, Mannheim, Germany. ¹³⁸Beijing Institute of Ophthalmology, Beijing Key Laboratory of Ophthalmology and Visual Sciences, Beijing Tongren Hospital, Capital Medical University, Beijing, China. ¹³⁹Geisinger Research, Biomedical and Translational Informatics Institute, Rockville, MD, USA. ¹⁴⁰Department of Clinical Physiology, Tampere University Hospital, Tampere, Finland. ¹⁴¹Department of Clinical Physiology, Finnish Cardiovascular Research Center—Tampere, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland. ¹⁴²Kyoto-McGill International Collaborative School in Genomic Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan. ¹⁴³Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA. ¹⁴⁴Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA. ¹⁴⁵Department of Medicine, Kuopio University Hospital, Kuopio, Finland. ¹⁴⁶Deutsches Herzzentrum München, Technische Universität München, Munich, Germany. ¹⁴⁷DZHK (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany. ¹⁴⁸Institute of Epidemiology and Biostatistics, University of Ulm, Ulm, Germany. ¹⁴⁹National Heart and Lung Institute, Imperial College London, London, UK. ¹⁵⁰Integrated Research and Treatment Center Adiposity Diseases, University of Leipzig, Leipzig, Germany. ¹⁵¹Division of Nephrology and Hypertension, Loyola University Chicago, Chicago, IL, USA. ¹⁵²Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Medical University of Innsbruck, Innsbruck, Austria. ¹⁵³RIKEN Center for Integrative Medical Sciences (IMS), Yokohama (Kanagawa), Japan. ¹⁵⁴The Department of Public Health Solutions, National Institute for Health and Welfare, Helsinki, Finland. ¹⁵⁵Diabetes and Obesity Research Program, University of Helsinki, Helsinki, Finland. ¹⁵⁶Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland, Kuopio, Finland. ¹⁵⁷Division of Biomedical Informatics and Personalized Medicine, School of Medicine, University of Colorado Denver—Anschutz Medical Campus, Aurora, CO, USA. ¹⁵⁸Department of Clinical Chemistry, Fimlab Laboratories, Tampere, Finland. ¹⁵⁹Department of Clinical Chemistry, Finnish Cardiovascular Research Center—Tampere, Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland. ¹⁶⁰Institute of Epidemiology and Biobank Popgen, Kiel University, Kiel, Germany. ¹⁶¹A list of members and affiliations appears in the Supplementary Note. ¹⁶²Diabetes Center, Khoo Teck Puat Hospital, Singapore, Singapore. ¹⁶³Cardiovascular Epidemiology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden. ¹⁶⁴Nuffield Department of Medicine, University of Oxford, Oxford, UK. ¹⁶⁵Broad Institute of Harvard and MIT, Cambridge, MA, USA. ¹⁶⁶Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore and National University Health System, Singapore, Singapore. ¹⁶⁷The Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ¹⁶⁸Target Sciences—Genetics, GlaxoSmithKline, Albuquerque, NM, USA. ¹⁶⁹Wellcome Trust Center for Human Genetics, University of Oxford, Oxford, UK. ¹⁷⁰Oxford Center for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK. ¹⁷¹Department of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, Munich, Germany. ¹⁷²Synlab Academy, Synlab Holding Deutschland GmbH, Mannheim, Germany. ¹⁷³Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria. ¹⁷⁴Medical Clinic V, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. ¹⁷⁵Laboratory of Clinical Genome Sequencing, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan. ¹⁷⁶Independent Research Group Clinical Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany. ¹⁷⁷Chair of Epidemiology, Ludwig-Maximilians-Universität München at UNIKA-T Augsburg, Augsburg, Germany. ¹⁷⁸Institute of Human Genetics, Helmholtz Zentrum München, Neuherberg, Germany. ¹⁷⁹Institute of Human Genetics, Technische Universität München, Munich, Germany. ¹⁸⁰Hypertension and Cardiovascular Disease, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden. ¹⁸¹Department of Psychiatry, VU University Medical Center, Amsterdam, the Netherlands. ¹⁸²Department of Genetics, University of North Carolina, Chapel Hill, NC, USA. ¹⁸³Institute for Molecular Bioscience, University of Queensland, St Lucia, Queensland, Australia. ¹⁸⁴Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, the Netherlands. ¹⁸⁵Center for Public Health Genomics, University of Virginia, Charlottesville, Charlottesville, VA, USA. ¹⁸⁶Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ¹⁸⁷Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA. ¹⁸⁸Data Tecnica International, Glen Echo, MD, USA. ¹⁸⁹Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany. ¹⁹⁰Department of Cardiology, Heart Center, Tampere University Hospital, Tampere, Finland. ¹⁹¹Department of Cardiology, Finnish Cardiovascular Research Center—Tampere, Faculty of Medicine and Life Sciences, Tampere University, Tampere, Finland. ¹⁹²Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA. ¹⁹³Section of Gerontology and Geriatrics, Department of Internal Medicine, Leiden University Medical Center, Leiden, the Netherlands. ¹⁹⁴University of Maryland School of Medicine, Baltimore, MD, USA. ¹⁹⁵Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA. ¹⁹⁶TIMI Study Group, Boston, MA, USA. ¹⁹⁷Department of Clinical Biochemistry, Landspítali University Hospital, Reykjavik, Iceland. ¹⁹⁸Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK. ¹⁹⁹Biochemistry, Wake Forest School of Medicine, Winston-Salem, NC, USA. ²⁰⁰Department of Medicine, Geriatrics Section, Boston Medical Center, Boston University School of Medicine, Boston, MA, USA. ²⁰¹National Institute for Health and Welfare, Helsinki, Finland. ²⁰²Institute of Genetic and Biomedical Research, National Research Council of Italy, UOS of Sassari, Li Punti, Sassari, Italy. ²⁰³Department of Psychiatry, University Hospital of

Lausanne, Lausanne, Switzerland. ²⁰⁴Faculty of Medicine, University of Split, Split, Croatia. ²⁰⁵Gen-info Ltd, Zagreb, Croatia. ²⁰⁶Service de Néphrologie, Geneva University Hospitals, Geneva, Switzerland. ²⁰⁷Center for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK. ²⁰⁸Einthoven Laboratory of Experimental Vascular Research, Leiden University Medical Center, Leiden, the Netherlands. ²⁰⁹Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, Turku, Finland. ²¹⁰Research Center of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, Finland. ²¹¹Institute of Physiology, University Medicine Greifswald, Karlsburg, Germany. ²¹²Harvard Medical School, Boston, MA, USA. ²¹³Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands. ²¹⁴Department of Health Sciences, University of Milan, Milano, Italy. ²¹⁵ePhood Scientific Unit, ePhood SRL, Milano, Italy. ²¹⁶NHS Blood and Transplant, BRC Oxford Haematology Theme; Nuffield Division of Clinical Laboratory Sciences; University of Oxford, Oxford, UK. ²¹⁷Division of Endocrinology, Diabetes and Nutrition, University of Maryland School of Medicine, Baltimore, MD, USA. ²¹⁸Molecular Biology and Biochemistry, Gottfried Schatz Research Center for Cell Signaling, Metabolism and Aging, Medical University of Graz, Graz, Austria. ²¹⁹Neuroalgology Unit, Fondazione IRCCS Istituto Neurologico 'Carlo Besta', Milan, Italy. ²²⁰Institute of Molecular Biology and Biochemistry, Center for Molecular Medicine, Medical University of Graz, Graz, Austria. ²²¹Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, USA. ²²²Gertrude H. Sergievsky Center, Columbia University Medical Center, New York, NY, USA. ²²³Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, USA. ²²⁴Division of Population Health and Genomics, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK. ²²⁵Human Genetics, Wellcome Sanger Institute, Hinxton, UK. ²²⁶Institute of Genetic Epidemiology, Helmholtz Zentrum München—German Research Center for Environmental Health, Neuherberg, Germany. ²²⁷Chair of Genetic Epidemiology, IBE, Faculty of Medicine, Ludwig-Maximilians-Universität München, München, Germany. ²²⁸Department of Endocrinology and Nephrology, University of Leipzig, Leipzig, Germany. ²²⁹Department of Clinical Science and Education, Karolinska Institutet, Södersjukhuset, Stockholm, Sweden. ²³⁰Department of Cardiology, Södersjukhuset, Stockholm, Sweden. ²³¹Duke-NUS Medical School, Singapore, Singapore. ²³²The Institute for Translational Genomics and Population Sciences, Department of Pediatrics, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA. ²³³Heart Center Leipzig, Leipzig, Germany. ²³⁴Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. ²³⁵CRCHUM, Montreal, Canada. ²³⁶Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina, Greece. ²³⁷Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. ²³⁸Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. ²³⁹Durrer Center for Cardiovascular Research, The Netherlands Heart Institute, Utrecht, the Netherlands. ²⁴⁰Department of Obstetrics and Gynecology, Institute for Medicine and Public Health, Vanderbilt University Medical Center, Nashville, TN, USA. ²⁴¹Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, Greifswald, Germany. ²⁴²Internal Medicine, Department of Medicine, Lausanne University Hospital, Lausanne, Switzerland. ²⁴³Cardiology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden. ²⁴⁴Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden. ²⁴⁵School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. ²⁴⁶Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China. ²⁴⁷Green Lane Cardiovascular Service, Auckland City Hospital and University of Auckland, Auckland, New Zealand. ²⁴⁸Center for Population Health Sciences, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK. ²⁴⁹Department of Ophthalmology, Tohoku University Graduate School of Medicine, Miyagi, Japan. ²⁵⁰Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, CA, USA. ²⁵¹Department of Medicine, Harbor-UCLA Medical Center, Torrance, CA, USA. ²⁵²Cardiovascular Health Research Unit, Department of Medicine, Department of Epidemiology, Department of Health Service, University of Washington, Seattle, WA, USA. ²⁵³Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA. ²⁵⁴Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, MS, USA. ²⁵⁵Division of Kidney, Urologic and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA. ²⁵⁶Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA. ²⁵⁷Kidney Health Research Institute (KHRI), Geisinger, Danville, PA, USA. ²⁵⁸Department of Nephrology, Geisinger, Danville, PA, USA. ²⁵⁹Institute of Physiology, University of Zurich, Zurich, Switzerland. ²⁶⁰Anatomic Pathology, University of Washington Medical Center, Seattle, WA, USA. ²⁶¹Geisinger Research, Biomedical and Translational Informatics Institute, Danville, PA, USA. ²⁶²Department of Nephrology and Rheumatology, Kliniken Südostbayern, Regensburg, Germany. ²⁶³Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences (IMS), Osaka, Japan. ²⁶⁴Department of Statistical Genetics, Osaka University Graduate School of Medicine, Osaka, Japan. ²⁶⁵Division of Epidemiology, Department of Medicine, Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, USA. ²⁶⁶Vanderbilt University Medical Center, Division of Nephrology & Hypertension, Nashville, TN, USA. A list of members and affiliations appears in the Supplementary Note.²⁶⁷These authors contributed equally: Matthias Wuttke, Yong Li, Man Li, Karsten B. Sieber, Mary F. Feitosa, Mathias Gorski. ²⁶⁸These authors jointly supervised this work: Iris M. Heid, Markus Scholz, Alexander Teumer, Anna Köttgen, Cristian Pattaro.

*e-mail: anna.koettgen@uniklinik-freiburg.de; cristian.pattaro@eurac.edu

**A catalogue of genetic loci associated with kidney function from
analyses of a million individuals**

Supplementary Materials

Matthias Wuttke, Yong Li, Man Li, Karsten B. Sieber, Mary F. Feitosa, Mathias Gorski *et al.*

Supplementary Note 1: Between-study heterogeneity and ancestry-related heterogeneity in the discovery meta-analysis.....	2
Supplementary Note 2: <i>Trans</i> -eQTL analysis.....	2
Supplementary Note 3: Details on the replication study: the Million Veteran’s Program (MVP)	3
Supplementary Figure 1: Analysis Flowchart	5
Supplementary Figure 2: Regional Association Plots	6
Supplementary Figure 3: Genetic Heritability	7
Supplementary Figure 4: BUN Manhattan plot	8
Supplementary Figure 5: Genetic Risk Score analysis	9
Supplementary Figure 6: Genetic correlation plot for eGFR	10
Supplementary Figure 7: Pathway and tissue enrichment analysis with DEPICT (eGFR)	11
Supplementary Figure 8: Pathway and tissue enrichment analysis with DEPICT (BUN)	12
Supplementary Figure 9: Co-localization of eGFR-association signals with gene expression across 44 GTEx tissues and two kidney tissues.....	13
Extended acknowledgements and study funding information	18

Supplementary Tables are provided separately as a spreadsheet.

Supplementary Note 1: Between-study heterogeneity and ancestry-related heterogeneity in the discovery meta-analysis

Before seeking replication, we evaluated results from the discovery meta-analysis for heterogeneity by design and heterogeneity related to ancestry. Most of the 308 SNPs showed homogeneous effects across studies (median $I^2=5\%$, interquartile range: 0-13%; **Supplementary Table 3; Figure 2A**). Only one index SNP had $I^2>50\%$ (*UMOD-PDILT* locus, $I^2=60\%$), where previously described heterogeneity^{1,2} is suspected to be age-related.³ We then investigated the heterogeneity of genetic effects that was correlated with ancestry using meta-regression⁴ (Methods) and identified three index SNPs with significant ancestry-related heterogeneity at the *LINC01362*, *GATM*, and *PSD4* loci (ancestry heterogeneity p-value (p-anc-het) $<0.05/308$; **Figure 2A, Supplementary Table 3**). The index SNP at *UMOD-PDILT* did not show evidence for ancestry-related heterogeneity (p-anc-het=0.59). These results do not support large differences in estimated effects across ancestries for the majority of the identified SNPs. Ancestry-specific results for all 308 index SNPs are reported in **Supplementary Table 4**.

Supplementary Note 2: *Trans*-eQTL analysis

Trans-eQTL annotation of the index SNPs was only performed using whole blood and peripheral blood mononuclear cells, for which eQTL datasets with large sample size were available (Methods). Based on the analysis of 5 non-overlapping EA genome-wide eQTL studies (sample size range 1469 - 6645, **Supplementary Table 14**), we identified, among others, a reproducible link of rs10774625 (12q24.11) with several transcripts, including one for the calcium-binding protein gene *S100A10* (1q21.3) and *STAT1* (2q32.2). *S100A10* encodes a subunit of annexin A2, which co-localizes with *PLA2R* at the cell surface and in extracellular vesicles from podocytes.⁵ Inhibition of *STAT1* has been reported to protect from glomerular mesangial cell senescence⁶ and to ameliorate renal oxidative stress⁷ (**Supplementary Table 15**).

Supplementary Note 3: Details on the replication study: the Million Veteran's Program (MVP)

Study definition. The MVP⁸ is an independent trans-ethnic study whose participants were recruited across 63 U.S. Veteran's Administration (VA) medical facilities. Written informed consent was obtained and all documents and protocols were approved by the VA Central Institutional Review Board.

Genotypes. DNA was genotyped using a customized Affymetrix Axiom Biobank Array chip with additional content added to provide coverage of African and Hispanic haplotypes, as well as markers for common diseases in the VA population. After QC, genotypes were pre-phased using EAGLE v2⁹ and imputed based on the 1000Gp3v5 reference panel using minimac3.¹⁰ Genotype PCs were estimated using FlashPCA.¹¹

Phenotype. Serum creatinine was assessed up to one year prior to MVP enrollment using isotope dilution mass spectrometry. GFR was estimated using the CKD-EPI equation¹² after excluding subjects on dialysis, transplant patients, amputees, individuals on HIV medications, and those with creatinine values of <0.4 mg/dl.

Additional epidemiological information. Diabetes was defined as use of anti-diabetic medications or by assignment of an International Classification of Diseases 9 (ICD-9) code for diabetes during the baseline period. Hypertension was defined as having an ICD-9 code for hypertension, being on antihypertensive drug or having ≥ 2 measures of systolic or diastolic blood pressure >140 mmHg or >90 mmHg, respectively.


Genome-wide association study. GWAS of eGFR on SNP dosage levels were performed by fitting linear regression models adjusted for age at creatinine measurement, age², sex, body mass index, and the first 10 genetic PCs, using SNPTTEST v2.5.4-beta.¹³ All GWAS were stratified by self-reported ethnicity (79.6% White non-Hispanic; 20.4% Black non-Hispanic), diabetes, and hypertension status. Results were combined across strata using fixed effects inverse-variance weighted meta-analysis in METAL.¹⁴ This analysis encompassed 280,722 individuals across all strata, of whom 216,518 were non-Hispanic Whites (EA).

References (Supplementary Material)

1. Kottgen, A. *et al.* New loci associated with kidney function and chronic kidney disease. *Nat Genet* **42**, 376-84 (2010).
2. Pattaro, C. *et al.* Genetic associations at 53 loci highlight cell types and biological pathways relevant for kidney function. *Nat Commun* **7**, 10023 (2016).
3. Gudbjartsson, D.F. *et al.* Association of variants at UMOD with chronic kidney disease and kidney stones-role of age and comorbid diseases. *PLoS Genet* **6**, e1001039 (2010).
4. Magi, R. *et al.* Trans-ethnic meta-regression of genome-wide association studies accounting for ancestry increases power for discovery and improves fine-mapping resolution. *Hum Mol Genet* **26**, 3639-3650 (2017).
5. Fresquet, M. *et al.* PLA2R binds to the annexin A2-S100A10 complex in human podocytes. *Sci Rep* **7**, 6876 (2017).
6. Jiao, S., Zheng, X., Yang, X., Zhang, J. & Wang, L. Losartan inhibits STAT1 activation and protects human glomerular mesangial cells from angiotensin II induced premature senescence. *Can J Physiol Pharmacol* **90**, 89-98 (2012).
7. Lopez-Sanz, L. *et al.* SOCS1-targeted therapy ameliorates renal and vascular oxidative stress in diabetes via STAT1 and PI3K inhibition. *Lab Invest* (2018).
8. Gaziano, J.M. *et al.* Million Veteran Program: A mega-biobank to study genetic influences on health and disease. *J Clin Epidemiol* **70**, 214-23 (2016).
9. Loh, P.R. *et al.* Reference-based phasing using the Haplotype Reference Consortium panel. *Nat Genet* **48**, 1443-1448 (2016).
10. Das, S. *et al.* Next-generation genotype imputation service and methods. *Nat Genet* **48**, 1284-1287 (2016).
11. Abraham, G. & Inouye, M. Fast principal component analysis of large-scale genome-wide data. *PLoS One* **9**, e93766 (2014).
12. Levey, A.S. *et al.* A new equation to estimate glomerular filtration rate. *Ann Intern Med* **150**, 604-12 (2009).
13. Marchini, J., Howie, B., Myers, S., McVean, G. & Donnelly, P. A new multipoint method for genome-wide association studies by imputation of genotypes. *Nat Genet* **39**, 906-13 (2007).
14. Willer, C.J., Li, Y. & Abecasis, G.R. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* **26**, 2190-1 (2010).

Supplementary Figure 1: Analysis Flowchart

Locus discovery analysis in the trans-ethnic sample and fine-mapping analysis in EA participants.




Supplementary Figure 2: Regional Association Plots

Regional Association Plot Booklet for all 308 loci identified in association with eGFR through trans-ethnic meta-analyses.

The PDF booklet is available online as a separate download with the Supplementary Information.


Supplementary Figure 3: Genetic Heritability

Distribution of the genetic heritability (h^2) estimates of age- and sex-adjusted log(eGFR) residuals in the Cooperative Health Research In South Tyrol (CHRIS) study, for index SNPs from the trans-ethnic GWAS. h^2 distribution is shown before (gray) and after (green) inclusion of the index SNPs into the model, with the shift representing the amount of h^2 explained by the index SNPs.




Supplementary Figure 4: BUN Manhattan plot

Manhattan plot of results from the GWAS meta-analysis of blood urea nitrogen (BUN).




Supplementary Figure 5: Genetic Risk Score analysis

Association between lower genetically-predicted eGFR based on a genetic risk score (GRS) and ICD-10 based clinical diagnoses from 452,264 individuals from the UK Biobank. Asthma is included as a negative control. The GRS was derived as described in the Methods. Displayed are odds ratios and their 95% CIs per 10% lower GRS-predicted eGFR. Dark gray is used for results from the 147 SNPs likely to be most relevant for kidney function (same as in **Figure 2D**), light gray is used for results from all 264 replicated eGFR-associated index SNPs.



Supplementary Figure 6: Genetic correlation plot for eGFR


Genetic correlation plot based on the summary statistics from the trans-ethnic GWAS meta-analysis of eGFR and 748 other complex traits and diseases available through LD Hub.



The genetic correlations with citrate and cystatin C were not significant ($P=6.0 \times 10^{-4}$ and 4.0×10^{-4} , respectively, **Supplementary Table 7**), because these traits were measured in a limited number of studies, resulting in smaller GWAS sample sizes.


Supplementary Figure 7: Pathway and tissue enrichment analysis with DEPICT (eGFR)

Shown is the barplot of the results of the tissue and cell type enrichment analysis in **Panel A**. Cells, tissues and physiological systems are highlighted in blue if the association false discovery rate (FDR) was <0.05 and are summarized in the table in **Panel B**. The strongest enrichment was observed for urogenital and renal physiological systems and tissues: kidney, kidney cortex, and urinary tract. We additionally found significant enrichment for mucous membrane, respiratory mucosa, nasal mucosa, and nose (enrichment p-values from 3.1×10^{-4} to 1.2×10^{-3}), possibly reflecting epithelial cell processes including transport mechanisms shared with the kidney. **Panel C** illustrates the highly correlated and strongly associated meta gene sets ($P < 1. \times 10^{-6}$, FDR<0.05) from the pathway and gene-set enrichment analysis clustered according to their biological relevance for kidney function, energy metabolism and signaling and transcription.



Supplementary Figure 8: Pathway and tissue enrichment analysis with DEPICT (BUN)

Shown is the barplot of the results of the tissue and cell type enrichment analysis. Cells, tissues and physiological systems are highlighted in blue if the association FDR was <0.05 . Tissue and cell-type enrichment analysis of BUN-associated SNPs with $P < 5 \times 10^{-8}$ highlighted a very similar pattern to the one observed for eGFR: the strongest enrichment was observed for urogenital and renal physiological systems and tissues, and significant enrichment was also observed for mucous membrane, respiratory mucosa, nasal mucosa, nose, epithelial cells and the epithelium.



Supplementary Figure 9: Co-localization of eGFR-association signals with gene expression across 44 GTEx tissues and two kidney tissues

All eGFR loci were tested for co-localization with all eQTLs where the eQTL cis-window overlapped (± 100 kb) the sentinel genetic variants. Genes with at least one positive co-localization (posterior probability of one common causal variant, H_4 , ≥ 0.80) in any of the 44 tissues for which eQTL data was released by the GTEx Project or in two renal tissue are illustrated with the respective sentinel variants (Y-axis). Co-localizations across all tissues (X-axis) are illustrated as dots, where the size of the dots indicates the posterior probability of the co-localization. Negative co-localizations (posterior probability of $H_4 < 0.80$) are grey, while the positive co-localizations are color-coded based on the predicted change in expression relative to the allele associated with lower eGFR.

Extended acknowledgements and study funding information

The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the National Heart, Lung, and Blood Institute, the National Institutes of Health, or the US Department of Health and Human Services.

AA-DHS NIH R01 DK071891 (Barry I. Freedman, PI); NIH R01 NS075107 (Barry I. Freedman, PI).

ADVANCE ADVANCE genomic sub-studies were supported by grants from the Ministry of Science and Innovation from the Quebec Government, from Genome Quebec, from the Consortium Québécois du Médicament, from the Canadian Institutes of Health Research and from Medpharmgene, OPTITHERA Inc and Les Laboratoires Servier.

AFTER EU The AFTER EU study is the Danish part of the EURAGEDIC study which was supported by the European Commission (contract QLG2-CT-2001–01669). The genotyping for this study was part of the Genetics of Diabetic Nephropathy (GenDN) study, primarily funded by Juvenile Diabetes Research Foundation (JDRF) International Prime Award Number 17-2013-8. Tarunveer S Ahluwalia was also funded by the GenDN study grant and Lundbeck foundation Travel Grant (Ref. Number 2013-14471).

AGES This study has been funded by NIA contract N01-AG-12100 and HHSN271201200022C with contributions from NEI, NIDCD and NHLBI, the NIA Intramural Research Program, Hjartavernd (the Icelandic Heart Association), and the Althingi (the Icelandic Parliament). The study is approved by the Icelandic National Bioethics Committee, VSN: 00-063. The researchers thank the participants for their willingness to participate in the study.

Airwave We thank all participants in the Airwave Health Monitoring Study. The Airwave Health Monitoring Study is funded by the UK Home Office (780-TETRA) with additional support from the National Institute for Health Research (NIHR), and the Imperial College Biomedical Research Centre in collaboration with Imperial College NHS Healthcare Trust. The views expressed are those of the authors and not necessarily those of the sponsors. PE acknowledges support from the Medical Research Council and Public Health England (MR/L01341X/1) for the MRC-PHE Centre for Environment and Health; and the NIHR Health Protection Research Unit in Health Impact of Environmental Hazards (HPRU-2012-10141). This work used computing resources of the UK MEDical BIOinformatics partnership (UK MED-BIO supported by the Medical Research Council (MR/L01632X/1). PE is supported by the UK Dementia Research Institute which receives its funding from UK DRI Ltd funded by the UK Medical Research Council, Alzheimer's Society and Alzheimer's Research UK. PE is associate director of the Health Data Research UK London funded by a consortium led by the UK Medical Research Council.

Amish We thank the Amish research volunteers for their long-standing partnership in research, and the research staff at the Amish Research Clinic for their work and dedication. The Amish contribution was supported by NIH grants R01 AG18728, R01 HL088119, U01 GM074518, U01 HL072515, U01 HL084756, and NIH K12RR023250, and P30 DK072488. Additional

support was provided by the University of Maryland General Clinical Research Center, grant M01 RR 16500, the Baltimore Veterans Administration Medical Center Geriatrics Research, and the Paul Beeson Physician Faculty Scholars in Aging Program.

- ARIC** The Atherosclerosis Risk in Communities study has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services (contract numbers HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700004I and HHSN268201700005I), R01HL087641, R01HL086694; National Human Genome Research Institute contract U01HG004402; and National Institutes of Health contract HHSN268200625226C. The authors thank the staff and participants of the ARIC study for their important contributions. Infrastructure was partly supported by Grant Number UL1RR025005, a component of the National Institutes of Health and NIH Roadmap for Medical Research. The work of Anna Köttgen was supported by a Heisenberg Professorship (KO 3598/3-1) as well as CRCs 1140 and 992 of the German Research Foundation.
- ASPS, ASPS-Fam** The authors thank the staff and the participants for their valuable contributions. We thank Birgit Reinhart for her long-term administrative commitment, Elfi Hofer for the technical assistance at creating the DNA bank, Ing. Johann Semmler and Anita Harb for DNA sequencing and DNA analyses by TaqMan assays and Irmgard Poelzl for supervising the quality management processes after ISO9001 at the biobanking and DNA analyses. The research reported in this article was funded by the Austrian Science Fond (FWF) grant number P20545-P05, P13180 and PI904 as well as by the Austrian National Bank (OeNB) Anniversary Fund grant number P15435 and the Austrian Federal Ministry of Science, Research and Economy under the aegis of the EU Joint Programme-Neurodegenerative Disease Research (JPND)-www.jpnd.eu. The Medical University of Graz supports the databank of the ASPS.
- BBJ** The BioBank Japan project is supported by the Ministry of Education, Culture, Sports, Sciences and Technology of Japanese government and the Japan Agency for Medical Research and Development.
- BES** BES was supported by the National Key Laboratory Fund, Beijing, China.
- BioMe** The Mount Sinai IPM Biobank Program is supported by The Andrea and Charles Bronfman Philanthropies. Ruth Loos is funded by R01DK110113, U01HG007417, R01DK101855, and R01DK107786.
- CHNS** The China Health and Nutrition Survey (CHNS) was supported by the China National Institute of Nutrition and Food Safety; the China Center for Disease Control; the National Institutes of Health (R01HD30880, R01HL108427, and R01DK104371); the Fogarty International Center of the National Institutes of Health; the China-Japan Friendship Hospital; the Chinese Ministry of Health; and the Carolina Population Center (R24 HD050924). Cassandra N. Spracklen was supported by the American Heart Association Postdoctoral Fellowship (17POST3650016).
- CHRIS** Full acknowledgements for the CHRIS study are reported at <http://translational-medicine.biomedcentral.com/articles/10.1186/s12967-015-0704-9#Declarations>. The CHRIS study was funded by the Department of Innovation, Research, and University of the Autonomous

Province of Bolzano-South Tyrol.

- CHS** Cardiovascular Health Study: This CHS research was supported by NHLBI contracts HHSN268201200036C, HHSN268200800007C, HHSN268201800001C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086; and NHLBI grants U01HL080295, R01HL087652, R01HL105756, R01HL103612, R01HL120393, and U01HL130114 with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided through R01AG023629 from the National Institute on Aging (NIA). A full list of principal CHS investigators and institutions can be found at CHS-NHLBI.org. The provision of genotyping data was supported in part by the National Center for Advancing Translational Sciences, CTSI grant UL1TR001881, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
- Cilento** We thank the populations of Cilento for their participation in the study. This work was supported by grants from the Italian Ministry of Universities and Research and CNR (Interomics Flagship Project, PON03PE_00060_7), the Assessorato Ricerca Regione Campania, the Fondazione con il SUD (2011-PDR-13), and the Istituto Banco di Napoli - Fondazione to Marina Ciullo.
- CoLaus** The CoLaus|PsyCoLaus study was and is supported by research grants from GlaxoSmithKline, the Faculty of Biology and Medicine of Lausanne, and the Swiss National Science Foundation (grants 3200B0-105993, 3200B0-118308, 33CSCO-122661, 33CS30-139468 and 33CS30-148401).
- CROATIA-Korcula,**
CROATIA-Split,
CROATIA-Vis 10001 Dalmatians: The Croatian Biobank (CROATIA) The CROATIA-Vis, CROATIA-Korcula and CROATIA-Split were funded by grants from the Medical Research Council (UK), from the Republic of Croatia Ministry of Science, Education and Sports (108-1080315-0302; 216-1080315-0302) and the Croatian Science Foundation (8875); and the CROATIA-Korčula genotyping was funded by the European Union framework program 6 project EUROSPAN (LSHGCT2006018947). We thank the staff of several institutions in Croatia that supported the field work, including Zagreb Medical Schools, the Institute for Anthropological Research in Zagreb, the recruitment team from the Croatian Centre for Global Health, University of Split and all the study participants. We are grateful to the Helmholtz Zentrum Munchen (Munich, Germany), AROS Applied Biotechnology, (Aarhus, Denmark) and the Edinburgh Clinical Research facility, University of Edinburgh (Edinburgh, United Kingdom) for SNP array genotyping. Genetic analyses were supported by the MRC HGU “QTL in Health and Disease” core programme.
- CZECH POST-MONICA** The study was supported by research grant 15-27109A provided by the Health Research Agency of the Ministry of Health, Czech Republic; Krka, tovarna zdravil, d.d., Novo mesto, Slovenia; Servier s.r.o., Czech Republic.
- DECODE** The study was funded by deCODE Genetics/Amgen inc. We thank the study subjects for their valuable participation and our colleagues, who contributed to data collection, sample handling, and genotyping.

- DESIR** The D.E.S.I.R. study has been funded by INSERM contracts with Caisse nationale de l'assurance Maladie des Travailleurs Salariés (CNAMTS), Lilly, Novartis Pharma, and Sanofi-Aventis; INSERM (Réseaux en Santé Publique, Interactions entre les déterminants de la santé, Cohortes Santé TGIR 2008); the Association Diabète Risque Vasculaire; the Fédération Française de Cardiologie; La Fondation de France; Association de Langue Française pour l'Etude du Diabète et des Maladies Métaboliques (ALFEDIAM)/Société Francophone de Diabétologie (SFD); l'Office National Interprofessionnel des Vins (ONIVINS); Ardix Medical; Bayer Diagnostics; Becton Dickinson; Cardionics; Merck Santé; Novo Nordisk; Pierre Fabre; Roche; Topcon.
The D.E.S.I.R. Study Group. INSERM U1018: B. Balkau, P. Ducimetière, E. Eschwège; INSERM U367: F. Alhenc-Gelas; CHU D'Angers: Y Gallois, A. Girault; Centre de Recherche des Cordeliers, INSERM U1138, Bichat Hospital: F. Fumeron, M. Marre, R. Roussel; CHU de Rennes: F. Bonnet; CNRS UMR8090, Lille: A. Bonnefond, S. Cauchi, P. Froguel; Centres d'Examens de Santé: Alençon, Angers, Blois, Caen, Chateauroux, Chartres, Cholet, Le Mans, Orléans, Tours; Institut de Recherche Médecine Générale: J. Cogneau; General practitioners of the region; Institut inter-régional pour la Santé: C. Born, E. Caces, M. Cailleau, O Lantieri, J.G. Morea.
- Diabetic Cohort** The Diabetic Cohort (DC) was supported by the individual research grant from the National Medical Research Council (NMRC) and the Biomedical Research Council (BMRC) of Singapore. The Genome Institute of Singapore provided services for genotyping.
- DIACORE** Cohort recruiting and management was funded by the KfH Stiftung Präventivmedizin e.V. (Carsten A. Böger). Genome-wide genotyping was funded the Else Kröner-Fresenius-Stiftung (2012_A147), the KfH Stiftung Präventivmedizin and the University Hospital Regensburg. Data analysis was funded by the Else Kröner-Fresenius Stiftung (2012_A147) and by the Deutsche Forschungsgemeinschaft with grant DFG BO 3815/1-4. The work of Iris M. Heid and Carsten A. Böger was supported by DFG CRC 1350 / C6 and and DFG BO 3815/4-1.
- EGCUT** The EGCUT studies were financed by Estonian Government (grants IUT20-60 and IUT24-6) and by European Commission through the European Regional Development Fund in the frame of grant Estonian Center of Genomics/Roadmap II (project No. 2014-2020.4.01.16-0125) and grant GENTRANSMED (Project No. 2014-2020.4.01.15-0012) and through H2020 grant no 692145 (ePerMed).
- ERF** The Erasmus Rucphen Family (ERF) has received funding from the Centre for Medical Systems Biology (CMSB) and Netherlands Consortium for Systems Biology (NCSB), both within the framework of the Netherlands Genomics Initiative (NGI)/Netherlands Organization for Scientific Research (NWO). ERF study is also a part of EUROSPAN (European Special Populations Research Network) (FP6 STRP grant number 018947 (LSHG-CT-2006-01947)); European Network of Genomic and Genetic Epidemiology (ENGAGE) from the European Community's Seventh Framework Programme (FP7/2007-2013)/grant agreement HEALTH-F4-2007-201413; "Quality of Life and Management of the Living Resources" of 5th Framework Programme (no. QLG2-CT-2002-01254); FP7 project

EUROHEADPAIN (nr 602633), the Internationale Stichting Alzheimer Onderzoek (ISAO); the Hersenstichting Nederland (HSN); and the JNPD under the project PERADES (grant number 733051021, Defining Genetic, Polygenic and Environmental Risk for Alzheimer's Disease using multiple powerful cohorts, focused Epigenetics and Stem cell metabolomics). We thank all study participants and their relatives, general practitioners and neurologists for their contributions and to P. Veraart for her help in genealogy, J. Vergeer for the supervision of the laboratory work, and P. Snijders M.D. for his help in data collection of the data. Jun Liu, Cornelia M. van Duijn, and Ayse Demirkan have used exchange grants from the Personalized pREvention of Chronic Diseases consortium (PRECeDI). Ayse Demirkan is supported by a Veni grant (2015) from ZonMw.

- ESTHER** The ESTHER study was funded by the Saarland state Ministry for Social Affairs, Health, Women and Family Affairs (Saarbrücken, Germany), the Baden-Württemberg state Ministry of Science, Research and Arts (Stuttgart, Germany), the Federal Ministry of Education and Research (Berlin, Germany) and the Federal Ministry of Family Affairs, Senior Citizens, Women and Youth (Berlin, Germany).
- FamHS** The study was supported by grant R01-DK-089256 from NIDDK and grant R01HL117078 from NHLBI.
- FHS** The Framingham Heart Study is supported by HHSN268201500001.
- FINCAVAS** The Finnish Cardiovascular Study (FINCAVAS) has been financially supported by the Competitive Research Funding of the Tampere University Hospital (Grant 9M048 and 9N035), the Finnish Cultural Foundation, the Finnish Foundation for Cardiovascular Research, the Emil Aaltonen Foundation, Finland, the Tampere Tuberculosis Foundation, and EU Horizon 2020 (grant 755320 for TAXINOMISIS). The authors thank the staff of the Department of Clinical Physiology for collecting the exercise test data.
- Finrisk** We thank all individuals who participated in Finrisk surveys. Veikko Salomaa and Mikko Kuokkanen were supported by the Finnish Foundation for Cardiovascular Research. Mikko Kuokkanen was also supported by Päivikki and Sakari Sohlberg Foundation. We thank the CSC – IT center for science, Finland, for providing computational resources.
- GCKD** The GCKD study was funded by the German Ministry of Research and Education (Bundesministerium für Bildung und Forschung, BMBF), by the Foundation KfH Stiftung Präventivmedizin and by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – Projektnummer 246781735 – SFB 1140. Unregistered grants to support the study were provided by Bayer, Fresenius Medical Care and Amgen. Genotyping was supported by Bayer Pharma AG. Uromodulin measurements in GCKD were supported by the Swiss National Centre of Competence in Research Kidney Control of Homeostasis program and the Swiss National Science Foundation grant 31003A_169850. The work of Matthias Wuttke was supported by DFG CRC 1140 and the Else Kroener Fresenius Forschungskolleg NAKSYS. The work of Yong Li was supported by DFG KO 3598/4-1. The work of Anselm Hoppmann was partly supported by NIDDK R01 DK087635-09.

Generation R The Generation R Study is conducted by the Erasmus Medical Center in close collaboration with the School of Law and Faculty of Social Sciences of the Erasmus University Rotterdam, the Municipal Health Service Rotterdam area, Rotterdam, the Rotterdam Homecare Foundation, Rotterdam and the Stichting Trombosedienst & Artsenlaboratorium Rijnmond (STAR-MDC), Rotterdam. We acknowledge the contribution of children and parents, general practitioners, hospitals, midwives and pharmacies in Rotterdam. The generation and management of GWAS genotype data for the Generation R Study was done at the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, the Netherlands. We would like to thank Karol Estrada, Dr. Tobias A. Knoch, Anis Abuseiris, Luc V. de Zeeuw, and Rob de Graaf, for their help in creating GRIMP, BigGRID, MediGRID, and Services@MediGRID/D-Grid, [funded by the German Bundesministerium fuer Forschung und Technology; grants 01 AK 803 A-H, 01 IG 07015 G] for access to their grid computing resources. We thank Pascal Arp, Mila Jhamai, Marijn Verkerk, Manoushka Ganesh, Lizbeth Herrera and Marjolein Peters for their help in creating, managing and QC of the GWAS database. The general design of Generation R Study is made possible by financial support from the Erasmus MC, University Medical Center, Rotterdam, the Netherlands Organization for Health Research and Development (ZonMw) and the Ministry of Health, Welfare and Sport. Janine Felix and Vincent Jaddoe received additional funding from the European Union's Horizon 2020 research and innovation programme (733206, LIFECYCLE). Fernando Rivadeneira received additional funding from the Netherlands Organization for Health Research and Development (VIDI 016. 136. 367). This project received additional funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 633595 (DynaHEALTH). Vincent Jaddoe received additional funding from the Netherlands Organization for Health Research and Development (VIDI 016.136.361), European Research Council (ERC Consolidator Grant, ERC-2014-CoG-648916) and European Union's FP-7 programme (Early Nutrition).

GS:SFHS Generation Scotland received core support from the Chief Scientist Office of the Scottish Government Health Directorates [CZD/16/6] and the Scottish Funding Council [HR03006]. We thank all the families who took part, the general practitioners and the Scottish School of Primary Care for their help in recruiting them, and the whole Generation Scotland team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists, healthcare assistants and nurses. Genotyping of the GS:SFHS samples was carried out by the Genetics Core Laboratory at the Edinburgh Clinical Research Facility, University of Edinburgh, Scotland and was funded by the Medical Research Council UK and the Wellcome Trust (Wellcome Trust Strategic Award "STratifying Resilience and Depression Longitudinally" (STRADL) Reference 104036/Z/14/Z).

GSK Funding Source: Max-Planck Society, German Federal Ministry of Education and Research (BMBF) in the framework of the National Genome Research Network (NGFN), Foerderkennzeichen 01GS0481.

HANDLS The authors thank all study participants and the Healthy Aging in

Neighborhoods of Diversity across the Life Span (HANDLS) study medical staff for their contributions. The HANDLS study was supported by the Intramural Research Program of the NIH, National Institute on Aging and the National Center on Minority Health and Health Disparities (project # Z01-AG000513 and human subjects protocol number 09-AG-N248). Data analyses for the HANDLS study utilized the high-performance computational resources of the Biowulf Linux cluster at the National Institutes of Health, Bethesda, MD. (<http://biowulf.nih.gov>; <http://hpc.nih.gov>).

HYPERGENES Funding Source: HYPERGENES project (FP7-HEALTH-F4-2007-201550) and InterOmics (PB05 MIUR-CNR Italian Flagship Project).

INGI-CARL The project was approved by the local administration of Carlantino, the Health Service of Foggia Province, Italy, and ethical committee of the IRCCS Burlo-Garofolo of Trieste. We thank the people of Carlantino for their support.

INGI-FVG Project co-financed by the European Regional Development Fund under the Regional Operational Programme of Friuli Venezia Giulia - Objective "Regional Competitiveness and Employment" 2007/2013, Telethon Foundation (GGP09037), Fondo Trieste (2008), Regione FVG (L.26.2008), and Italian Ministry of Health (RC16/06, ART. 13 D.LGS 297/99) (to Paolo Gasparini). We thank the people of Friuli Venezia Giulia Region for their support.

INGI-VBI The research was supported by funds from Compagnia di San Paolo, Torino, Italy; Fondazione Cariplo, Italy and Ministry of Health, Ricerca Finalizzata 2011 and CCM 2010 to Daniela Toniolo. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We thank the inhabitants of the VB that made this study possible, the local administrations, the Tortona and Genova archdiocese and the ASL-22, Novi Ligure (AI) for support. We thank Clara Camaschella for data collection supervision and organization of the clinical data collection, Fiammetta Viganò for technical help, and Corrado Masciullo for the analysis platform.

INTERVAL We thank all INTERVAL voluntary participants. We thank the INTERVAL study co-ordination teams (at the Universities of Cambridge and Oxford and at NHS Blood and Transplant [NHSBT]), including the blood donation staff at the 25 static centers, for their help with INTERVAL participant recruitment and study fieldwork, as well as the Cambridge BioResource and NHSBT staff for their help with volunteer recruitment. We thank members of the Cambridge BioResource Scientific Advisory Board and Management Committee for their support of our study and the NIH Research Cambridge Biomedical Research Centre for funding (RG64219). The INTERVAL academic coordinating centre receives core support from the UK Medical Research Council (G0800270), the BHF (SP/09/002), the NIHR, and Cambridge Biomedical Research Centre, as well as grants from the European Research Council (268834), the European Commission Framework Programme 7 (HEALTH-F2-2012-279233), MSD, and Pfizer. The INTERVAL study is funded by NHSBT (11-01-GEN) and has been supported by the NIHR-BTRU in Donor Health and Genomics (NIHR BTRU-2014-10024) at the University of Cambridge in partnership with

NHSBT. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, the Department of Health of England, or NHSBT. The Cardiovascular Epidemiology Unit at the University of Cambridge is funded by UK MRC (G0800270), BHF (SP/09/002), UK NIHR Cambridge Biomedical Research Centre, ERC (268834), and European Commission Framework Programme 7 (HEALTH-F2-2012-279233). Willem H. Ouwehand is a NIHR Senior Investigator. David J. Roberts was supported by the NIHR Programme “Erythropoiesis in Health and Disease” (NIHR-RP-PG-0310-1004). John Danesh is a BHF Professor, European Research Council Senior Investigator, and NIHR Senior Investigator. Nicole Soranzo is supported by the Wellcome Trust (WT098051 and WT091310), the EU FP7 (EPIGENESYS 257082 and BLUEPRINT HEALTH-F5-2011-282510).

JHS The Jackson Heart Study (JHS) is supported and conducted in collaboration with Jackson State University (HHSN268201800013I), Tougaloo College (HHSN268201800014I), the Mississippi State Department of Health (HHSN268201800015I/HHSN26800001) and the University of Mississippi Medical Center (HHSN268201800010I, HHSN268201800011I and HHSN268201800012I) contracts from the National Heart, Lung, and Blood Institute (NHLBI) and the National Institute for Minority Health and Health Disparities (NIMHD). The authors also wish to thank the staffs and participants of the JHS. James G. Wilson is supported by U54GM115428 from the National Institute of General Medical Sciences. Laura M. Raffield is supported by T32 HL129982.

JUPITER The JUPITER trial and its genetic substudy were funded by AstraZeneca.

KORA The KORA research platform (KORA, Cooperative Health Research in the Region of Augsburg) was initiated and financed by the Helmholtz Zentrum München - German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education and Research and by the State of Bavaria. Furthermore, KORA research was supported within the Munich Center of Health Sciences (MC Health), Ludwig-Maximilians-Universität, as part of LMUinnovativ. Statistical KORA analyses were supported by DFG BO-3815/4-1 (to Carsten A. Böger) and BMBF 01ER1206 and 01ER1507 (to Iris M. Heid) and by University of Regensburg.

LIFE-Adult, LIFE-Heart, LIFE-Child LIFE-Adult, LIFE-Heart, and LIFE-Child, are funded by the Leipzig Research Center for Civilization Diseases (LIFE). LIFE is an organizational unit affiliated to the Medical Faculty of the University of Leipzig. LIFE is funded by means of the European Union, by the European Regional Development Fund (ERDF) and by funds of the Free State of Saxony within the framework of the excellence initiative.

Lifelines The Lifelines Cohort Study, and generation and management of GWAS genotype data for the Lifelines Cohort Study is supported by the Netherlands Organization of Scientific Research NWO (grant 175.010.2007.006), the Economic Structure Enhancing Fund (FES) of the Dutch government, the Ministry of Economic Affairs, the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the Northern Netherlands Collaboration of Provinces (SNN), the Province of Groningen, University Medical Center Groningen, the

University of Groningen, Dutch Kidney Foundation and Dutch Diabetes Research Foundation. The authors wish to acknowledge the services of the Lifelines Cohort Study, the contributing research centers delivering data to Lifelines, and all the study participants.

Living-biobank The genotyping was funded by the Agency for Science, Technology and Research, Singapore (<https://www.a-star.edu.sg/>), and by Merck Sharp & Dohme Corp., Whitehouse Station, NJ USA (<http://www.merck.com>). The participants were from the MEC study (funded by the Biomedical Research Council (BMRC 03/1/27/18/216), National Medical Research Council (0838/2004), National Research Foundation (through BMRC 05/1/21/19/425 and 11/1/21/19/678), Ministry of Health, Singapore, National University of Singapore and National University Health System, Singapore), and The SH2012 study (funded by the Ministry of Health, Singapore, National University of Singapore and National University Health System, Singapore).

LLFS The study was supported by grants: U01AG023746, U01AG023712, U01AG023749, U01AG023755, and U01AG023744 from NIA.

LOLIPOP The LOLIPOP study is supported by the National Institute for Health Research (NIHR) Comprehensive Biomedical Research Centre Imperial College Healthcare NHS Trust, the British Heart Foundation (SP/04/002), the Medical Research Council (G0601966, G0700931), the Wellcome Trust (084723/Z/08/Z, 090532 & 098381) the NIHR (RP-PG-0407-10371), the NIHR Official Development Assistance (ODA, award 16/136/68), the European Union FP7 (EpiMigrant, 279143), and H2020 programs (iHealth-T2D, 643774). We acknowledge support of the MRC-PHE Centre for Environment and Health, and the NIHR Health Protection Research Unit on Health Impact of Environmental Hazards. The work was carried out in part at the NIHR/Wellcome Trust Imperial Clinical Research Facility. The views expressed are those of the author(s) and not necessarily those of the Imperial College Healthcare NHS Trust, the NHS, the NIHR or the Department of Health. We thank the participants and research staff who made the study possible. JC is supported by the Singapore Ministry of Health's National Medical Research Council under its Singapore Translational Research Investigator (STaR) Award (NMRC/STaR/0028/2017).

LURIC LURIC was supported by the 7th Framework Program of the EU (AtheroRemo, grant agreement number 201668 and RiskyCAD, grant agreement number 305739). The work of W.M. and M.E.K. is supported as part of the Competence Cluster of Nutrition and Cardiovascular Health (nutriCARD) which is funded by the German Ministry of Education and Research (grant agreement no. 01EA1411A). The authors thank the LURIC study team involved in patient recruitment as well as sample and data handling, and the laboratory staff at the Ludwigshafen General Hospital and the universities of Freiburg, Ulm and Heidelberg, Germany.

MDC-CC This study was supported by the European Research Council (Consolidator grant nr 649021, Orho-Melander), the Swedish Research Council, the Swedish Heart and Lung Foundation, the Novo Nordisk Foundation, the Swedish Diabetes Foundation, and the Pålsson Foundation, and by equipment grants from the Knut and Alice Wallenberg

Foundation, the Region Skåne, Skåne University Hospital, the Linneus Foundation for the Lund University Diabetes Center and Swedish Foundation for Strategic Research for IRC15-0067.

- MESA** MESA and the MESA SHARe project are conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with MESA investigators. Support for MESA is provided by contracts HHSN268201500003I, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, UL1-TR-000040, UL1-TR-001079, UL1-TR-001420, UL1-TR-001881, and DK063491. MESA Family is conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with MESA investigators. Support is provided by grants and contracts R01HL071051, R01HL071205, R01HL071250, R01HL071251, R01HL071258, R01HL071259, by the National Center for Research Resources, Grant UL1RR033176, and the National Center for Advancing Translational Sciences, Grant UL1TR001881. This publication was developed under a STAR research assistance agreement, No. RD831697 (MESA Air), awarded by the U.S Environmental protection Agency. It has not been formally reviewed by the EPA. The views expressed in this document are solely those of the authors and the EPA does not endorse any products or commercial services mentioned in this publication.
- METSIM** Michael Boehnke was supported by NIH grant DK062370.
- MICROS** We thank all study participants, all primary care practitioners, and the personnel of the Hospital of Silandro (Department of Laboratory Medicine) for their participation and collaboration in the research project. The study was supported by the Ministry of Health and Department of Educational Assistance, University and Research of the Autonomous Province of Bolzano, the South Tyrolean Sparkasse Foundation, and the European Union framework program 6 EUROSPAN project (contract no. LSHG-CT-2006-018947).
- MVP** This work was supported by the MVP-VA Award #I01BX003360 (PI Adriana M. Hung).
- MyCode (Geisinger)** We would like to acknowledge the participants, staff, and our colleagues associated with the Geisinger MyCode Community Health Initiative. We also thank the staff of the PACDC of Geisinger for assistance with the phenotypic data, and the staff of the Biomedical & Translational Informatics and Kidney Health Research Institute.
- NEO** The authors of the NEO study thank all individuals who participated in the Netherlands Epidemiology in Obesity study, all participating general practitioners for inviting eligible participants and all research nurses for collection of the data. We thank the NEO study group, Pat van Beelen, Petra Noordijk and Ingeborg de Jonge for the coordination, lab and data management of the NEO study. The genotyping in the NEO study was supported by the Centre National de Génotypage (Paris, France), headed by Jean-Francois Deleuze. The NEO study is supported by the participating Departments, the Division and the Board of Directors of the Leiden University Medical Center, and by the Leiden University, Research

Profile Area Vascular and Regenerative Medicine. Dennis Mook-Kanamori is supported by Dutch Science Organization (ZonMW-VENI Grant 916.14.023).

- NESDA** The infrastructure for the NESDA study (www.nesda.nl) is funded through the Geestkracht program of the Netherlands Organisation for Health Research and Development (ZonMw, grant no. 10-000-1002) and financial contributions by participating universities and mental health care organizations (VU University Medical Center, GGZ inGeest, Leiden University Medical Center, Leiden University, GGZ Rivierduinen, University Medical Center Groningen, University of Groningen, Lentis, GGZ Friesland, GGZ Drenthe, and Rob Giel Onderzoekscentrum). Statistical analyses were carried out on the Genetic Cluster Computer (<http://www.geneticcluster.org>), which is financially supported by the Netherlands Scientific Organization (NWO 480-05-003) along with a supplement from the Dutch Brain Foundation.
- OGP** The Ogliastra Genetic Park study was supported by grant from the Italian Ministry of Education, University and Research (MIUR) no. 5571/DSPAR/2002. We thank all study participants for their contributions and the municipal administrations for their economic and logistic support.
- ORCADES** The Orkney Complex Disease Study (ORCADES) was supported by the Chief Scientist Office of the Scottish Government (CZB/4/276, CZB/4/710), a Royal Society URF to James F. Wilson, the MRC Human Genetics Unit quinquennial programme “QTL in Health and Disease”, Arthritis Research UK and the European Union framework program 6 EUROSPAN project (contract no. LSHG-CT-2006-018947). DNA extractions were performed at the Wellcome Trust Clinical Research Facility in Edinburgh. We would like to acknowledge the invaluable contributions of the research nurses in Orkney, the administrative team in Edinburgh, the people of Orkney, and the data analysts in particular Dr Thibaud Boutin for the genotype imputation to the HRC reference panel.
- PIVUS** The ULSAM study was supported by Wellcome Trust grants WT098017, WT064890, WT090532, Uppsala University, Uppsala University Hospital, the Swedish Research Council and the Swedish Heart-Lung Foundation. Cecilia M. Lindgren is supported by the Li Ka Shing Foundation, WT-SSI/John Fell funds and by the NIHR Biomedical Research Centre, Oxford, by Widenlife and NIH (5P50HD028138-27). Johan Ärnlöv was supported by The Swedish Research Council, Swedish Heart-Lung Foundation, Dalarna University and Uppsala University
- PREVEND** The Prevention of Renal and Vascular Endstage Disease Study (PREVEND) genetics is supported by the Dutch Kidney Foundation (Grant E033), the EU project grant GENECURE (FP-6 LSHM CT 2006 037697), the National Institutes of Health (grant LM010098), the Netherlands organization for health research and development (NWO VENI grant 916.761.70), and the Dutch Inter University Cardiology Institute Netherlands (ICIN). Niek Verweij was supported by NWO VENI grant 016.186.125.
- POPGEN** The PopGen 2.0 network was supported by a grant from the German Ministry for Education and Research (01EY1103). Sandra Freitag-Wolf was supported by German Research Foundation, Clusters of Excellence 306,

Inflammation at Interfaces.

QIMR adolescent We acknowledge funding by Australian National Health and Medical Research Council (NHMRC) grants 241944, 339462, 389927, 389875, 389891, 389892, 389938, 442915, 442981, 496739, 552485, 552498 and Australian Research Council grants A7960034, A79906588, A79801419, DP0770096, DP0212016, DP0343921 for building and maintaining the adolescent twin family resource through which samples were collected.

QIMR adult We acknowledge the contributions of many staff in the Genetic Epidemiology Unit, Queensland Institute of Medical Research, in interviewing study participants, sample processing and DNA extraction, and data management. Funding for aspects of this work was provided by the Australian National Health and Medical Research Council (241944, 339462, 389927, 389875, 389891, 389892, 389938, 442915, 442981, 496739, 552485, 552498), the Australian Research Council (A7960034, A79906588, A79801419, DP0770096, DP0212016, DP0343921), the EU 5th Framework Programme GenomEUtwin Project (QLG2-CT-2002-01254), and the U.S. National Institutes of Health (AA07535, AA10248, AA11998, AA13320, AA13321, AA13326, AA14041, AA17688, DA12854, MH66206). G.W.M. was supported by National Health and Medical Research Council (NHMRC) Fellowship Schemes.

RS The Rotterdam Study (RS) has been approved by the Medical Ethics Committee of the Erasmus MC (registration number MEC 02.1015) and by the Dutch Ministry of Health, Welfare and Sport (Population Screening Act WBO, license number 1071272-159521-PG). The RS has been entered into the Netherlands National Trial Register (NTR; www.trialregister.nl) and into the WHO International Clinical Trials Registry Platform (ICTRP; www.who.int/ictrp/network/primary/en/) under shared catalogue number NTR6831. All participants provided written informed consent to participate in the study and to have their information obtained from treating physicians. The generation and management of GWAS genotype data for the RS (RS I, RS II, RS III) was executed by the Human Genotyping Facility of the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands. The GWAS datasets are supported by the Netherlands Organisation of Scientific Research NWO Investments (nr. 175.010.2005.011, 911-03-012), the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, the Research Institute for Diseases in the Elderly (014-93-015; RIDE2), the Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO) Netherlands Consortium for Healthy Aging (NCHA), project nr. 050-060-810. We thank Pascal Arp, Mila Jhamai, Marijn Verkerk, Lizbeth Herrera and Marjolein Peters, MSc, and Carolina Medina-Gomez, MSc, for their help in creating the GWAS database, and Karol Estrada, PhD, Yurii Aulchenko, PhD, and Carolina Medina-Gomez, MSc, for the creation and analysis of imputed data. The RS is funded by Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands Organization for the Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. The authors are grateful to the study

participants, the staff from the RS and the participating general practitioners and pharmacists.

- SCES** The Singapore Chinese Eye Study (SCES) was supported by grants from the National Medical Research Council (STaR/0003/2008), the Singapore Bio Imaging Consortium (C-011/2006) and the Biomedical Research Council (08/1/35/19/550). The Genome Institute of Singapore provided services for genotyping.
- SHIP/SHIP-Trend** SHIP is part of the Community Medicine Research net of the University of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research (grants no. 01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of Cultural Affairs as well as the Social Ministry of the Federal State of Mecklenburg-West Pomerania, and the network 'Greifswald Approach to Individualized Medicine (GANI_MED)' funded by the Federal Ministry of Education and Research (grant 03IS2061A). Genome-wide data have been supported by the Federal Ministry of Education and Research (grant no. 03ZIK012) and a joint grant from Siemens Healthineers, Erlangen, Germany and the Federal State of Mecklenburg- West Pomerania. The University of Greifswald is a member of the Caché Campus program of the InterSystems GmbH.
- SiMES** The Singapore Malay Eye Study (SiMES) was funded by the National Medical Research Council (NMRC 0796/2003 and NMRC/STaR/0003/2008) and Biomedical Research Council (BMRC, 09/1/35/19/616). The Genome Institute of Singapore provided services for genotyping.
- SINDI** The Singapore Indian Eye Study (SINDI) was funded by grants from the Biomedical Research Council of Singapore (BMRC 09/1/35/19/616 and 08/1/35/19/550), and the National Medical Research Council of Singapore (NMRC/STaR/0003/2008). The Genome Institute of Singapore provided services for genotyping.
- SCHS - CHD cases and controls** The Singapore Chinese Health Study was supported by the National Institutes of Health, USA (RO1 CA144034 and UM1 CA182876), the nested case-control study of myocardial infarction by the Singapore National Medical Research Council (NMRC 1270/2010), and genotyping by the HUU-CREATE Programme of the National Research Foundation, Singapore (Project Number 370062002).
- SKIPOGH** The SKIPOGH study was supported by a Swiss national science foundation grant (FN33CM30-124087 and FN33CM30-140331), by the Swiss National Centres of Competence in Research Kidney and TransCure. Olivier Devuyst was supported by Swiss National Science Foundation (project grant 31003A-169850) and the Swiss National Centre of Competence in Research (NCCR) Kidney Control of Homeostasis (Kidney.CH).
- SOLID-TIMI 52** The SOLID-TIMI 52 trial was supported and funded by grants from GlaxoSmithKline.
- Sorbs** This work was supported by grants from the German Research Foundation (SFB-1052 "Obesity mechanisms" A01, B03, SPP 1629 TO 718/2- 1), from the German Diabetes Association, from the DHFD (Diabetes Hilfs- und Forschungsfonds Deutschland) and from IFB Adiposity Diseases (AD2-060E, AD2-06E95, AD2-06E99). IFB Adiposity Diseases is supported by

the Federal Ministry of Education and Research (BMBF), Germany, FKZ: 01EO1501.

SP2 The Singapore Prospective Study Program (SP2) were supported by the individual research grant and clinician scientist award schemes from the National Medical Research Council (NMRC) and the Biomedical Research Council (BMRC) of Singapore. The Genome Institute of Singapore provided services for genotyping.

STABILITY The STABILITY trial was supported and funded by grants from GlaxoSmithKline.

TRAILS TRAILS (TRacking Adolescents' Individual Lives Survey) is a collaborative project involving various departments of the University Medical Center and University of Groningen, the University of Utrecht, the Radboud Medical Center Nijmegen, and the Parnassia Bavo group, all in the Netherlands. TRAILS has been financially supported by grants from the Netherlands Organization for Scientific Research NWO (Medical Research Council program grant GB-MW 940-38-011; ZonMW Brainpower grant 100-001-004; ZonMw Risk Behavior and Dependence grant 60-60600-97-118; ZonMw Culture and Health grant 261-98-710; Social Sciences Council medium-sized investment grants GB-MaGW 480-01-006 and GB-MaGW 480-07-001; Social Sciences Council project grants GB-MaGW 452-04-314 and GB-MaGW 452-06-004; NWO large-sized investment grant 175.010.2003.005; NWO Longitudinal Survey and Panel Funding 481-08-013 and 481-11-001); the Dutch Ministry of Justice (WODC), the European Science Foundation (EuroSTRESS project FP-006), Biobanking and Biomolecular Resources Research Infrastructure BBMRI-NL (CP 32), the participating universities, and Accare Center for Child and Adolescent Psychiatry. Statistical analyses were carried out on the Genetic Cluster Computer (<http://www.geneticcluster.org>), which is financially supported by the Netherlands Scientific Organization (NWO 480-05-003) along with a supplement from the Dutch Brain Foundation. We are grateful to all adolescents who participated in this research and to everyone who worked on this project and made it possible.

TwinGene TwinGene is a sub-study of the Swedish Twin Registry which is managed by Karolinska Institutet and receives funding through the Swedish Research Council under the grant no 2017-00641. TwinGene was supported by grants from the Swedish Research Council (M-2005-1112), GenomEUtwin (EU/QLRT-2001-01254; QLG2-CT-2002-01254), NIH DK U01-066134, The Swedish Foundation for Strategic Research (SSF). Heart and Lung foundation no. 20070481. Analysis on renal biomarkers was supported by grants from Stockholm County Council, The Swedish Society of Medicine (SLS-412071), the Serafimer Hospital Foundation and Stiftelsen för Njursjuka.

ULSAM The ULSAM study was supported by Wellcome Trust grants WT098017, WT064890, WT090532, Uppsala University, Uppsala University Hospital, the Swedish Research Council and the Swedish Heart-Lung Foundation. Johan Ärnlöv was supported by The Swedish Research Council, Swedish Heart-Lung Foundation, Dalarna University and Uppsala University.

Vanderbilt The data used for the analyses were obtained from Vanderbilt University Medical Center's BioVU, which is supported by numerous sources:

institutional funding, private agencies, and federal grants. These include the NIH funded Shared Instrumentation Grant S10RR025141; and CTSA grants UL1TR002243, UL1TR000445, and UL1RR024975. Genomic data are also supported by investigator-led projects that include U01HG004798, R01NS032830, RC2GM092618, P50GM115305, U01HG006378, U19HL065962, R01HD074711; and additional funding sources listed at <https://victr.vanderbilt.edu/pub/biovu/>. Jacklyn N. Hellwege is supported by the Vanderbilt Molecular and Genetic Epidemiology of Cancer training program, funded by T32CA160056.

VIKING The Viking Health Study – Shetland (VIKING) was supported by the MRC Human Genetics Unit quinquennial programme grant “QTL in Health and Disease”. DNA extractions and genotyping were performed at the Edinburgh Clinical Research Facility, University of Edinburgh. We acknowledge the contributions of the research nurses in Shetland, the administrative team in Edinburgh, the people of Shetland, and the data analysts, in particular Dr Thibaud Boutin for the genotype imputation to the HRC reference panel.

WGHS The Women's Genome Health Study (WGHS) is supported by the National Heart, Lung, and Blood Institute (HL043851 and HL080467) and the National Cancer Institute (CA047988 and UM1CA182913) with funding for genotyping provided by Amgen.

YFS The Young Finns Study has been financially supported by the Academy of Finland: grants 286284, 134309 (Eye), 126925, 121584, 124282, 129378 (Salve), 117787 (Gendi), and 41071 (Skidi); the Social Insurance Institution of Finland; Competitive State Research Financing of the Expert Responsibility area of Kuopio, Tampere and Turku University Hospitals (grant X51001); Juho Vainio Foundation; Paavo Nurmi Foundation; Finnish Foundation for Cardiovascular Research; Finnish Cultural Foundation; The Sigrid Juselius Foundation; Tampere Tuberculosis Foundation; Emil Aaltonen Foundation; Yrjö Jahnsson Foundation; Signe and Ane Gyllenberg Foundation; Diabetes Research Foundation of Finnish Diabetes Association; and EU Horizon 2020 (grant 755320 for TAXINOMISIS); and European Research Council (grant 742927 for MULTIEPIGEN project); Tampere University Hospital Supporting Foundation. We thank the teams that collected data at all measurement time points; the persons who participated as both children and adults in these longitudinal studies; and biostatisticians Irina Lisinen, Johanna Ikonen, Noora Kartiosuo, Ville Aalto, and Jarno Kankaanranta for data management and statistical advice.

Variant annotation was supported by software resources provided via the Caché Campus program of the InterSystems GmbH to Alexander Teumer.

LifeLines Cohort Study – Author Group

Behrooz Z Alizadeh (1), H Marike Boezen (1), Lude Franke (2), Pim van der Harst (3), Gerjan Navis (4), Marianne Rots (5), Morris Swertz (2), Bruce HR Wolffenbuttel (6), Cisca Wijmenga (2)

- (1) Department of Epidemiology, University of Groningen, University Medical Center Groningen, The Netherlands
- (2) Department of Genetics, University of Groningen, University Medical Center Groningen, The Netherlands
- (3) Department of Cardiology, University of Groningen, University Medical Center Groningen, The Netherlands
- (4) Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, The Netherlands
- (5) Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, The Netherlands
- (6) Department of Endocrinology, University of Groningen, University Medical Center Groningen, The Netherlands

Million Veteran Program: Consortium Acknowledgement

MVP Executive Committee

- Co-Chair: J. Michael Gaziano, M.D., M.P.H.
- Co-Chair: Rachel Ramoni, D.M.D., Sc.D.
- Jim Breeling, M.D. (ex-officio)
- Kyong-Mi Chang, M.D.
- Grant Huang, Ph.D.
- Sumitra Muralidhar, Ph.D.
- Christopher J. O'Donnell, M.D., M.P.H.
- Philip S. Tsao, Ph.D.

MVP Program Office

- Sumitra Muralidhar, Ph.D.
- Jennifer Moser, Ph.D.

MVP Recruitment/Enrollment

- Recruitment/Enrollment Director/Deputy Director, Boston – Stacey B. Whitbourne, Ph.D.; Jessica V. Brewer, M.P.H.
- MVP Coordinating Centers
 - o Clinical Epidemiology Research Center (CERC), West Haven – John Concato, M.D., M.P.H.
 - o Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque - Stuart Warren, J.D., Pharm D.; Dean P. Argyres, M.S.
 - o Genomics Coordinating Center, Palo Alto – Philip S. Tsao, Ph.D.
 - o Massachusetts Veterans Epidemiology Research Information Center (MAVERIC), Boston - J. Michael Gaziano, M.D., M.P.H.
 - o MVP Information Center, Canandaigua – Brady Stephens, M.S.
- Core Biorepository, Boston – Mary T. Brophy M.D., M.P.H.; Donald E. Humphries, Ph.D.
- MVP Informatics, Boston – Nhan Do, M.D.; Shahpoor Shayan
- Data Operations/Analytics, Boston – Xuan-Mai T. Nguyen, Ph.D.

MVP Science

- Genomics - Christopher J. O'Donnell, M.D., M.P.H.; Saiju Pyarajan Ph.D.; Philip S. Tsao, Ph.D.
- Phenomics - Kelly Cho, M.P.H, Ph.D.
- Data and Computational Sciences – Saiju Pyarajan, Ph.D.
- Statistical Genetics – Elizabeth Hauser, Ph.D.; Yan Sun, Ph.D.; Hongyu Zhao, Ph.D.

MVP Local Site Investigators

- Atlanta VA Medical Center (Peter Wilson)
- Bay Pines VA Healthcare System (Rachel McArdle)
- Birmingham VA Medical Center (Louis Dellitalia)

- Cincinnati VA Medical Center (John Harley)
- Clement J. Zablocki VA Medical Center (Jeffrey Whittle)
- Durham VA Medical Center (Jean Beckham)
- Edith Nourse Rogers Memorial Veterans Hospital (John Wells)
- Edward Hines, Jr. VA Medical Center (Salvador Gutierrez)
- Fayetteville VA Medical Center (Gretchen Gibson)
- VA Health Care Upstate New York (Laurence Kaminsky)
- New Mexico VA Health Care System (Gerardo Villareal)
- VA Boston Healthcare System (Scott Kinlay)
- VA Western New York Healthcare System (Junzhe Xu)
- Ralph H. Johnson VA Medical Center (Mark Hamner)
- Wm. Jennings Bryan Dorn VA Medical Center (Kathlyn Sue Haddock)
- VA North Texas Health Care System (Sujata Bhushan)
- Hampton VA Medical Center (Pran Iruvanti)
- Hunter Holmes McGuire VA Medical Center (Michael Godschalk)
- Iowa City VA Health Care System (Zuhair Ballas)
- Jack C. Montgomery VA Medical Center (Malcolm Buford)
- James A. Haley Veterans' Hospital (Stephen Mastorides)
- Louisville VA Medical Center (Jon Klein)
- Manchester VA Medical Center (Nora Ratcliffe)
- Miami VA Health Care System (Hermes Florez)
- Michael E. DeBakey VA Medical Center (Alan Swann)
- Minneapolis VA Health Care System (Maureen Murdoch)
- N. FL/S. GA Veterans Health System (Peruvemba Sriram)
- Northport VA Medical Center (Shing Shing Yeh)
- Overton Brooks VA Medical Center (Ronald Washburn)
- Philadelphia VA Medical Center (Darshana Jhala)
- Phoenix VA Health Care System (Samuel Aguayo)
- Portland VA Medical Center (David Cohen)
- Providence VA Medical Center (Satish Sharma)
- Richard Roudebush VA Medical Center (John Callaghan)
- Salem VA Medical Center (Kris Ann Oursler)
- San Francisco VA Health Care System (Mary Whooley)
- South Texas Veterans Health Care System (Sunil Ahuja)
- Southeast Louisiana Veterans Health Care System (Amparo Gutierrez)
- Southern Arizona VA Health Care System (Ronald Schiffman)
- Sioux Falls VA Health Care System (Jennifer Greco)
- St. Louis VA Health Care System (Michael Rauchman)
- Syracuse VA Medical Center (Richard Servatius)
- VA Eastern Kansas Health Care System (Mary Oehlert)
- VA Greater Los Angeles Health Care System (Agnes Wallbom)
- VA Loma Linda Healthcare System (Ronald Fernando)
- VA Long Beach Healthcare System (Timothy Morgan)
- VA Maine Healthcare System (Todd Stapley)

- VA New York Harbor Healthcare System (Scott Sherman)
- VA Pacific Islands Health Care System (Gwenevere Anderson)
- VA Palo Alto Health Care System (Philip Tsao)
- VA Pittsburgh Health Care System (Elif Sonel)
- VA Puget Sound Health Care System (Edward Boyko)
- VA Salt Lake City Health Care System (Laurence Meyer)
- VA San Diego Healthcare System (Samir Gupta)
- VA Southern Nevada Healthcare System (Joseph Fayad)
- VA Tennessee Valley Healthcare System (Adriana Hung)
- Washington DC VA Medical Center (Jack Lichy)
- W.G. (Bill) Hefner VA Medical Center (Robin Hurley)
- White River Junction VA Medical Center (Brooks Robey)
- William S. Middleton Memorial Veterans Hospital (Robert Striker)